This article reviews the use of ChEIs (Aricept, Exelon, and Razadyne) in PSP and other non-Alzheimer’s disorders. There is “only a limited case for recommending ChEIs in” PSP.
Robin
Expert Review of Neurotherapeutics. 2010 Nov;10(11):1699-705.
Cholinesterase inhibitors: beyond Alzheimer’s disease.
Larner AJ.
Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Abstract
Cholinesterase inhibitors (ChEIs) are widely licensed for the symptomatic treatment of Alzheimer’s disease, but their use has also been examined in a wide variety of neurological disorders besides Alzheimer’s disease, and this article reviews these uses.
The evidence currently available suggests that ChEIs may possibly have a role in the treatment of some patients with dementia with Lewy bodies and Parkinson’s disease dementia, but at this point in time there would seem to be only a limited case for recommending ChEIs in mild cognitive impairment, Down syndrome, progressive supranuclear palsy, pure vascular dementia, frontotemporal lobar degeneration, Huntington’s disease, multiple sclerosis, epilepsy, delirium, traumatic brain injury, sleep-related disorders or certain psychiatric disorders (e.g., schizophrenia and bipolar disorder).
Clinical practice with respect to non-Alzheimer’s disease indications for ChEIs may vary according to jurisdiction, specifically with regards to whether national guidelines effectively limit off-licence drug use.
PubMed ID#: 21046692